Scientific Advisory Board
Stephen H. Safe, D.Phil.
Distinguished Professor and Sid Kyle Professor of Toxicology,
Health Science Center, Texas A&M University
Dr. Safe is recognized in the area of the molecular biology of endocrine disruption chemicals, mechanisms of toxicity, and the mechanisms and therapeutics of Breast Cancer. He has served on various national and international committees, received numerous awards and has published over five hundred articles in peer-reviewed periodicals and journals.
Robert A. Newman, Ph.D.
Professor Emeritus, University of Texas, M.D. Anderson Cancer Center
Chief Science Officer, New Chapter, Inc.
Dr. Newman has been involved in the development of pharmaceutical drugs for over twenty four years at MD Anderson Cancer Center (MDACC); he has nine issued patents, over three-hundred peer-reviewed published articles, is the author of several books and has served as a consultant to more than a dozen pharmaceutical companies in the area of drug and natural product development. Recently retired from MDACC, he presently serves as CSO of a major nutriceutical in New England and as a major science advisor to several companies including Phoenix Biotechnology (San Antonio, TX), Nerium Biotechnology (San Antonio, TX), Salient Pharmaceuticals (Houston, TX) and Health2O (Dallas, TX).
Tetsushi Inada, Ph.D.
President & Managing Director
Pharma-East Insight, Inc
Dr. Inada has over twenty five years of US and international experience in the clinical development of drug compounds including several oncology candidates. He has successfully guided licensing and partnering efforts with Japanese and US companies and is a tremendous addition to the Plantacor advisory group.
George A. Clay, Ph.D.
Regulatory Expert & Consultant
Dr. Clay has over thirty-five years of experience in clinical development and regulatory affairs in both the US and international regulatory environments. He has worked for several companies during this time and been responsible for the NDA approvals of compounds such as Ambien, Arthrotec, Cytotec, Daypro, Flagyl, Maxaquin, Nordotropin, Novoseven, Avapro, Plavix, Skelid and he consulted on the approval for oxaliplatin (Eloxitin). Many of these drugs have generated annual revenues in excess of a billion dollars with their respective companies.